OTHER INFORMATION
−Removed: the three months ended March 31, 2024,
−Removed: no director or officer of the Company adopted or terminated a “Rule
−Removed: trading arrangement” or
−Removed: trading arrangement,” as each term is defined in Item 408(a) of Regulation
+Added: During the six months ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1
+Added: trading arrangement” or “non-Rule
+Added: trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The following exhibits are being filed herewith, or incorporated by reference into, this Quarterly Report on Form 10-Q and are numbered in accordance with Item 601 of Regulation S-K:
+Added: Amended and Restated Business Combination Agreement, dated as of May 23, 2024, between Bellevue Life Sciences Acquisition Corp.
+Added: and OSR Holdings Co., Ltd.
+Added: (Incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on May 30, 2024)*
Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No.
12 unchanged sentences
333-264597) filed with the SEC on May 10, 2022)
−Removed: Promissory Note, dated February 9, 2024, issued by Bellevue Life Sciences Acquisition Corp.
−Removed: to Jun Chul Whang (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-41390) filed with the SEC on February 13, 2024)
−Removed: Promissory Note, dated March 8, 2024, issued by Bellevue Life Sciences Acquisition Corp.
−Removed: to Josh Pan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-41390) filed with the SEC on March 13, 2024)
+Added: Promissory Note, dated April 8, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: to Bellevue Global Life Sciences Investors LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on April 11, 2024)
+Added: Promissory Note, dated April 17, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: to Bellevue Global Life Sciences Investors LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on April 22, 2024)
+Added: Promissory Note, dated May 14, 2024, issued by Bellevue Life Sciences Acquisition Corp.
+Added: to Bellevue Global Life Sciences Investors LLC (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No.
+Added: 001-41390) filed with the SEC on May 14, 2024)
Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 **
11 unchanged sentences
Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101**
+Added: Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
+Added: A copy of any omitted schedule or exhibit will be furnished separately to the SEC upon request.
Filed herewith
2 unchanged sentences
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
+Added: August 19, 2024
/s/ Kuk Hyoun Hwang
2 unchanged sentences
(Principal Executive Officer)
+Added: August 19, 2024
Chief Financial Officer
−Removed: (Principal Financial Officer and Chief
−Removed: Accounting Officer)
+Added: (Principal Financial Officer and Chief Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.